Drug Involvement of Prenatally Exposed Children

产前暴露儿童的药物参与

• 批准号: 7113206
• 负责人: VERONICA H ACCORNERO
• 金额: $ 13.36万
• 依托单位: UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-09-01 至 2008-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7113206
• 关键词: African American; adolescence (12-20); clinical research; cocaine; developmental neurobiology; disease /disorder onset; disease /disorder proneness /risk; drug abuse; early experience; embryo /fetus toxicology; human subject; middle childhood (6-11); neuropharmacology; parent offspring interaction; psychopathology

DESCRIPTION (provided by applicant): The candidate is proposing a five-year career development plan to launch independent research on the topic of prenatal drug exposure as a risk factor for earlier onset and more rapid progression through stages of drug involvement (e.g., opportunity, first use, regular use, and dependence), with due consideration for susceptibility traits and other biological, psychological, and social/environmental influences. With licensure in child clinical psychology and postdoctoral training in drug dependence epidemiology, the candidate brings to this award expertise in child and adolescent development and psychopathology, rich clinical experiences to guide and inform her research efforts, knowledge of basic statistical methods, and a strong commitment to the study of early drug involvement. The multidisciplinary training plan includes mentorship from Dr. Clyde McCoy and other experienced senior NIDA-supported investigators, coursework/workshops, conferences, and consultation from content and methodological specialists. The centerpiece of the early award-supported activities will be a supervised research project focusing on the influence of prenatal cocaine exposure on the earliest stages of drug involvement. The starting model at this stage of the research plan is based on the testable idea that cocaine-exposed children will have earlier and more frequent opportunities to use drugs and will transition more rapidly from opportunity to first use between late childhood and middle adolescence. To this end, the candidate will gather new annual data in addition to analyzing data from an ongoing, longitudinal NIDA-funded study (R01DA06556; P.I.: E.S. Bandstra, co-sponsor) on the neurodevelopmental outcome of cocaine-exposed infants, who will again be assessed at age 12 years. Relationships between prenatal cocaine exposure and early drug involvement will be examined in the context of potential mediators already measured between birth and age 12 (e.g., executive functioning/attention, behavior problems), moderators (e.g., gender), and additional influences (e.g., deviant peers, ongoing maternal drug use). The candidate's own plan calls for the addition of measures of drug opportunities and sensation seeking during the 12-year visit, with annual follow-up assessments of these constructs via telephone as the children develop through adolescence. This K01 award will enable the candidate to devote full-time effort to NIDA research, while broadening her understanding of child and adolescent drug involvement and the longitudinal research methods (xxx; P.I.: J. C. Anthony, co-sponsor) and other content areas required to understand the interplay of early susceptibilities, environmental factors, and time-dependent influences that might shape the expression of prenatal drug exposure. This enhanced knowledge will be the foundation for the candidate's planning and implementation of her independent career in drug research.

描述(由申请人提供)： 候选人提出了一项为期五年的职业发展计划，以启动关于产前药物暴露这一主题的独立研究，该主题是通过药物参与的各个阶段(例如，机会、首次使用、经常使用和依赖)更早发病和更快进展的风险因素，并适当考虑易感性特征和其他生物、心理和社会/环境影响。凭借儿童临床心理学和药物依赖流行病学的博士后培训证书，候选人为该奖项带来了儿童和青少年发展和精神病理学方面的专业知识，丰富的临床经验来指导和指导她的研究工作，基本统计方法的知识，以及对早期药物参与研究的坚定承诺。多学科培训计划包括克莱德·麦考伊博士和其他由NIDA支持的经验丰富的高级调查人员的指导、课程作业/研讨会、会议以及内容和方法专家的咨询。早期获奖支持活动的中心将是一个有监督的研究项目，重点是产前接触可卡因对涉及毒品的早期阶段的影响。研究计划现阶段的启动模式是基于可测试的想法，即接触可卡因的儿童将有更早和更频繁的吸毒机会，并将在儿童期后期和青春期中期更快地从机会过渡到首次使用。为此，候选人除了分析NIDA资助的一项正在进行的关于可卡因暴露婴儿神经发育结果的纵向研究(R01DA06556；P.I.：E.S.Bandstra，共同发起人)的数据外，还将收集新的年度数据，这些婴儿将在12岁时再次接受评估。将在出生到12岁之间已经衡量的潜在中介因素(例如，执行功能/注意力、行为问题)、调节因素(例如，性别)和其他影响(例如，变态同伴、持续的母亲吸毒)的背景下，审查产前接触可卡因与早期药物参与之间的关系。这位候选人自己的计划要求在为期12年的访问期间增加吸毒机会和寻求刺激的措施，并通过电话对这些结构进行年度跟踪评估，因为孩子们在青春期期间一直在发育。这一K01奖项将使候选人能够全职致力于NIDA的研究，同时扩大她对儿童和青少年药物参与和纵向研究方法(XXX；P.I.：J.C.Anthony，共同发起人)和其他内容领域的理解，这些领域需要了解可能塑造产前药物暴露表现的早期易感性、环境因素和时间相关影响的相互作用。这些增强的知识将为候选人规划和实施她在药物研究方面的独立职业生涯奠定基础。